Comparison of demographic, haematological and biochemical parameters of HIV-positive patients that did (n = 26) or did not (n = 74) develop tenofovir-related adverse events (data were given as mean ± standard deviation).

*<p>chi square test.</p

Box-plot of Tenofovir (TDF) plasma trough concentrations measured in 100 HIV-infected patients.

<p>Box-plot of Tenofovir (TDF) plasma trough concentrations measured in 100 HIV-infected patients.</p

TDF plasma trough concentrations measured female (panel A) and male (panel B) HIV infected patients stratified according to median body weight (**p<0.01).

<p>TDF plasma trough concentrations measured female (panel A) and male (panel B) HIV infected patients stratified according to median body weight (**p<0.01).</p

Main demographic, haematological and biochemical parameters of HIV-positive patients given tenofovir as part of their maintenance antiretroviral therapy (data were given as mean ± standard deviation).

<p>Main demographic, haematological and biochemical parameters of HIV-positive patients given tenofovir as part of their maintenance antiretroviral therapy (data were given as mean ± standard deviation).</p

Distribution of atazanavir (ATV) plasma trough concentrations according to daily drug dosage.

<p>*given either as 400 mg qd or 200 mg bid; IQR: interquartile range</p><p>Distribution of atazanavir (ATV) plasma trough concentrations according to daily drug dosage.</p

Atazanavir (ATV) plasma trough concentrations measured in patients that did or did not experienced drug-related adverse events.

<p>Data were stratified also according to ritonavir use.</p><p>^patients that did not develop ATV-related adverse events;</p><p>*p<0.01 and</p><p>**p<0.05 vs. controls</p><p>Atazanavir (ATV) plasma trough concentrations measured in patients that did or did not experienced drug-related adverse events.</p

Main demographic, hematologic and biochemical characteristics of HIV-positive patients receiving atazanavir as part of their antiretroviral regimen.

<p>TDF: tenofovir; ABC: abacavir; RAL: raltegravir; GGT: gamma-glutamyltransferase; ALT: alanine aminotransferase; HCV: hepatitis C virus; HBV: hepatitis B virus; VL: viral load</p><p>Main demographic, hematologic and biochemical characteristics of HIV-positive patients receiving atazanavir as part of their antiretroviral regimen.</p

Box-plot of atazanavir (ATV) plasma trough concentrations clustered according to drug dosage.

<p>Dashed lines represent the upper and lower limits of the therapeutic window of ATV concentrations (150–800 ng/mL).</p

Univariate and multivariate regression analysis of clinical, demographic and pharmacological covariates associated with the development of atazanavir (ATV)-related dyslipidemia.

<p>r-value: correlation coefficient; GGT: gamma-glutamyltransferase; ALT: alanine aminotransferase; HCV: hepatitis C virus; HBV: hepatitis B virus; ATV: atazanavir</p><p>Univariate and multivariate regression analysis of clinical, demographic and pharmacological covariates associated with the development of atazanavir (ATV)-related dyslipidemia.</p

Clusters characteristics and Time of Most Recent Common Ancestor (TMRCA) stratified according to country of origin.

<p>Clusters characteristics and Time of Most Recent Common Ancestor (TMRCA) stratified according to country of origin.</p